The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ...

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ...

Earnings season continues as we highlight companies expected to report earnings the next trading day, helping investors prepare for the upcoming market action. Leading the charge are Square, Gilead ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

The company had earlier said that its Q2 financial results were expected to take a $61 million hit due to acquired in-process ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Orchestrate agents autonomously with A2A: Aisera Unify natively supports A2A protocol, enabling real-time coordination across AI agents. Agents are discovered via dynamic Agent Cards backed by the ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Patients with HIV had lower adherence to pre-exposure prophylaxis (PrEP) if they lived in areas with the lowest disadvantage.

Magrolimab triple therapy falls short of expectations in a study of previously untreated acute myeloid leukemia.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...